 |
 Video: What is a Stock Split?
|
|
|
| Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD. According to our AGIO split history records, Agios Pharmaceuticals has had 0 splits. | |
|
Agios Pharmaceuticals (AGIO) has 0 splits in our AGIO split history database.
Looking at the AGIO split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Agios Pharmaceuticals shares, starting with a $10,000 purchase of AGIO, presented on a split-history-adjusted basis factoring in the complete AGIO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$47.54 |
|
| End price/share: |
$29.03 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-38.94% |
|
| Average Annual Total Return: |
-4.82% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$6,103.44 |
|
| Years: |
9.99 |
|
|
|
|
|
